What Is The Difference Between Lewy Body Dementia And Alzheimer's Disease? 
Published on: March 5, 2025
What Is The Difference Between Lewy Body Dementia And Alzheimer's Disease? 
Article author photo

Atharva Deshpande

Master's degree, Clinical Pharmacology, University of Glasgow

Article reviewer photo

Khairat Salisu

Master of Public Health - MPH, Public Health, University of Nottingham

Overview

Understanding the differences between Lewy body dementia (LBD) and Alzheimer’s disease (AD) is crucial for patients, caregivers, and healthcare professionals alike. These two conditions, while both forms of dementia, present with distinct symptoms and require different approaches to management. This article will guide through these differences with clarity and depth for a better comprehension of these complex neurodegenerative disorders.

The primary difference between LBD and AD lies in their underlying causes and the way they affect the brain. LBD is characterised by the presence of Lewy bodies, abnormal protein deposits in the brain that disrupt normal brain function, leading to symptoms such as visual hallucinations, motor problems, and fluctuating cognition. In contrast, AD is marked by the accumulation of amyloid plaques and tau tangles in the brain, which primarily affect memory, thinking, and behaviour. These differences in brain pathology lead to distinct clinical presentations and progression patterns.

There’s much more to uncover about how these conditions differ in terms of symptoms, diagnosis, progression, and treatment. Understanding these nuances can greatly impact the care and support provided to individuals affected by these forms of dementia. Let’s dive deeper into the details.

Understanding lewy body dementia

LBD is the second most common form of dementia after AD, accounting for approximately 10-20% of all dementia cases.3 LBD is characterised by the presence of abnormal protein deposits known as Lewy bodies in the brain. These deposits disrupt the brain's normal functioning, leading to a range of cognitive, motor, and behavioural symptoms.

Causes

Lewy bodies are clumps of alpha-synuclein protein that accumulate in neurons. The exact cause of their formation is not fully understood, but they are closely related to Parkinson's disease, which also involves these protein deposits.7 The presence of Lewy bodies affects the brain's chemical signals, leading to a decline in thinking, movement, behaviour, and mood.8

Symptoms

The symptoms of LBD can be quite varied and often fluctuate, making it a challenging condition to diagnose. Common symptoms include:

  • Cognitive fluctuations: Patients may experience varying levels of alertness and attention, sometimes appearing fully functional and other times confused or disoriented8
  • Visual hallucinations: Seeing things that aren’t there is one of the hallmark symptoms of LBD, occurring early in the disease’s progression3
  • Motor symptoms: Similar to Parkinson’s disease, LBD can cause tremors, stiffness, and slowed movement2
  • REM sleep behaviour disorder: Individuals with LBD often act out their dreams, sometimes violently, due to a loss of normal muscle paralysis during REM sleep2

Progression

LBD typically progresses more rapidly than Alzheimer’s disease, with significant fluctuations in cognitive abilities from day to day or even hour to hour.3 The disease's progression leads to increasing difficulty with mobility, more severe hallucinations, and eventually, a loss of independence in daily activities.8

Diagnosis

Diagnosing LBD can be challenging due to its symptoms overlapping with both Alzheimer’s disease and Parkinson’s disease. It is typically diagnosed through a combination of clinical criteria, including a detailed medical history, neurological exams, and imaging studies like MRI or PET scans.3 Biomarkers, such as abnormal levels of alpha-synuclein, are also being researched as diagnostic tools.8

Understanding alzheimer’s disease

Alzheimer’s disease is the most common form of dementia, accounting for 60-80% of cases.1 It is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behaviour. AD is characterised by the buildup of amyloid plaques and tau tangles in the brain, which leads to the death of neurons and a gradual decline in cognitive function.5

Causes

The exact cause of AD is not fully understood, but it involves a combination of genetic, environmental, and lifestyle factors. The accumulation of amyloid plaques between neurons and tau tangles within neurons disrupts communication between brain cells and triggers inflammation, leading to cell death.5

Symptoms

AD typically presents with a different symptom profile compared to LBD, focusing more on cognitive decline, particularly in the following areas:

  • Memory loss: Difficulty remembering recent events, names, or conversations is usually one of the earliest and most prominent symptoms1
  • Language difficulties: As the disease progresses, individuals may struggle with finding the right words, following conversations, or understanding written and spoken language4
  • Disorientation: People with AD may become confused about time, place, or personal identity, leading to issues such as getting lost in familiar places4
  • Executive function impairment: Difficulty with planning, decision-making, and problem-solving can interfere with daily tasks like managing finances or preparing meals1

Progression

AD progresses gradually, with symptoms worsening over several years. Early stages might involve mild memory loss and difficulty with complex tasks, while later stages often involve severe memory impairment, loss of ability to communicate, and complete dependence on caregivers.1

Diagnosis

Diagnosis of AD usually involves a thorough medical evaluation, including cognitive testing, neurological exams, and brain imaging to detect the presence of amyloid plaques or loss of brain volume. Biomarkers in cerebrospinal fluid or blood are also being used increasingly to aid in the diagnosis.6

Key differences between Lewy body dementia and alzheimer’s disease

While both Lewy body dementia and Alzheimer’s disease are types of dementia, they have distinct differences that impact diagnosis, treatment, and management.

CategoryLewy Body Dementia (LBD)Alzheimer's Disease (AD)
PathologyCharacterised by the presence of Lewy bodies (alpha-synuclein protein deposits) in the brain8Marked by the accumulation of amyloid plaques and tau tangles that disrupt brain cell function and lead to cell death5
SymptomsEarly symptoms often include visual hallucinations, motor symptoms similar to Parkinson’s, and cognitive fluctuations3Memory loss is the most prominent early symptom, followed by language difficulties, disorientation, and impaired executive function1
Cognitive DeclineCognitive decline in LBD is often more rapid and fluctuates more than in AD8The cognitive decline in Alzheimer’s Disease tends to be gradual and continuous5
Response to TreatmentPatients with LBD may be highly sensitive to antipsychotic medications, which can worsen symptoms2Medications like cholinesterase inhibitors and memantine are often used to manage cognitive symptoms, though they are not curative1
PrognosisGenerally has a shorter life expectancy compared to Alzheimer’s disease, often due to complications from motor symptoms and susceptibility to infections2Progresses more slowly, but eventually leads to severe cognitive and physical decline, requiring full-time care1

FAQs

What is the primary difference between Lewy body dementia and alzheimer’s disease?

The primary difference lies in the brain changes that cause each condition. Lewy body dementia is caused by abnormal protein deposits called Lewy bodies, leading to fluctuating cognitive function and motor issues. Alzheimer’s Disease is caused by the buildup of amyloid plaques and tau tangles, leading to progressive memory loss and cognitive decline.

Can a person have both LBD and AD?

Yes, it is possible for an individual to have both LBD and AD, a condition known as mixed dementia. This can complicate the diagnosis and treatment, as symptoms from both conditions may be present.

How do the symptoms of LBD and AD affect daily life differently?

LBD often leads to pronounced visual hallucinations, motor problems, and fluctuating cognition, making day-to-day activities unpredictable. AD primarily affects memory and cognitive abilities, leading to gradual loss of independence in activities like managing finances, remembering appointments, and eventually personal care.

Are there specific risk factors for developing LBD or AD?

Age is a significant risk factor for both conditions. Genetic factors, such as mutations in the APOE gene, can increase the risk for AD, while Parkinson’s disease increases the risk for LBD. However, the exact causes remain complex and involve multiple factors.

What should caregivers know about managing these conditions?

Caregivers should be aware of the specific symptoms and challenges associated with each condition. For LBD, this includes managing hallucinations and motor symptoms, while for AD, the focus may be on memory support and cognitive therapies. Support groups, education, and healthcare guidance are essential for effective caregiving.

Summary

Lewy body dementia (LBD) and Alzheimer’s disease are both devastating forms of dementia but differ significantly in their underlying causes, symptoms, and progression. LBD is characterised by the presence of Lewy bodies and presents with fluctuating cognition, visual hallucinations, and motor symptoms, whereas Alzheimer’s Disease is marked by amyloid plaques and tau tangles, leading primarily to memory loss and cognitive decline. Understanding these differences is crucial for accurate diagnosis and effective management, as the approach to treatment and care can vary greatly depending on the specific condition.

As research continues to advance, early and accurate diagnosis of these conditions will improve, leading to better outcomes for those affected by these complex and challenging diseases.

References

  1. 2023 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia [Internet]. 2023 Apr [cited 2025 Mar 3];19(4):1598–695. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13016 
  2. Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder‐neurodegenerative disease association, evolving concepts, controversies, and future directions. Annals of the New York Academy of Sciences [Internet]. 2010 Jan [cited 2025 Mar 3];1184(1):15–54. Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.05115.x 
  3. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology [Internet]. 2017 Jul 4 [cited 2025 Mar 3];89(1):88–100. Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000004058 
  4. Morris JC. Mild cognitive impairment and preclinical Alzheimer’s disease. Geriatrics. 2005 Jun;Suppl:9–14.
  5. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in alzheimer disease. Cold Spring Harbor Perspectives in Medicine [Internet]. 2011 Sep 1 [cited 2025 Mar 3];1(1):a006189–a006189. Available from: http://perspectivesinmedicine.cshlp.org/lookup/doi/10.1101/cshperspect.a006189 
  6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia [Internet]. 2011 May [cited 2025 Mar 3];7(3):280–92. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2011.03.003 
  7. Spillantini MG, Goedert M. Synucleinopathies: past, present and future. Neuropathology Appl Neurobio [Internet]. 2016 Feb [cited 2025 Mar 3];42(1):3–5. Available from: https://onlinelibrary.wiley.com/doi/10.1111/nan.12311 
  8. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. The Lancet [Internet]. 2015 Oct [cited 2025 Mar 3];386(10004):1683–97. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673615004626 
Share

Atharva Deshpande

Master's degree, Clinical Pharmacology, University of Glasgow

Atharva Deshpande is a Clinical Pharmacology specialist with extensive experience in pharmacy dispensing, patient care, and pharmaceutical research. With a strong academic foundation that includes an MSc in Clinical Pharmacology from the University of Glasgow and a Bachelors in Pharmacy, Atharva has developed expertise in clinical practices, pharmaceutical quality control, and stock management.

His research has explored a potential treatment and biomarkers for Alzheimer’s disease and innovative approaches to oral cancer diagnostics. He is also skilled in precision laboratory techniques such as ELISA and qPCR and proficient in statistical tools like SPSS and GraphPad Prism.

In addition to his scientific pursuits, Atharva is passionate about contributing to the dissemination of healthcare knowledge through writing, aiming to bridge the gap between complex medical concepts and everyday understanding.

arrow-right